Reducing acetylated tau is neuroprotective in brain injury.

Acetylation Alzheimer Disease / etiology Animals Anti-Inflammatory Agents, Non-Steroidal / therapeutic use Biomarkers / blood Brain Injuries, Traumatic / complications Cell Line Diflunisal / therapeutic use Female Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) Humans Male Mice Mice, Inbred C57BL Neurons / metabolism Neuroprotection Salicylates / therapeutic use Sirtuin 1 / metabolism p300-CBP Transcription Factors / antagonists & inhibitors tau Proteins / blood
Alzheimer’s disease P7C3 acetylation congenital muscular dystrophy diflunisal neurodegeneration neuroprotection omigapil salsalate tau traumatic brain injury

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
13 05 2021
Historique:
received: 05 10 2020
revised: 21 01 2021
accepted: 15 03 2021
pubmed: 15 4 2021
medline: 22 12 2021
entrez: 14 4 2021
Statut: ppublish

Résumé

Traumatic brain injury (TBI) is the largest non-genetic, non-aging related risk factor for Alzheimer's disease (AD). We report here that TBI induces tau acetylation (ac-tau) at sites acetylated also in human AD brain. This is mediated by S-nitrosylated-GAPDH, which simultaneously inactivates Sirtuin1 deacetylase and activates p300/CBP acetyltransferase, increasing neuronal ac-tau. Subsequent tau mislocalization causes neurodegeneration and neurobehavioral impairment, and ac-tau accumulates in the blood. Blocking GAPDH S-nitrosylation, inhibiting p300/CBP, or stimulating Sirtuin1 all protect mice from neurodegeneration, neurobehavioral impairment, and blood and brain accumulation of ac-tau after TBI. Ac-tau is thus a therapeutic target and potential blood biomarker of TBI that may represent pathologic convergence between TBI and AD. Increased ac-tau in human AD brain is further augmented in AD patients with history of TBI, and patients receiving the p300/CBP inhibitors salsalate or diflunisal exhibit decreased incidence of AD and clinically diagnosed TBI.

Identifiants

DOI: 10.1016/j.cell.2021.03.032 PMID: 33852912 PMC: PMC8491234
pubmed: 33852912
pii: S0092-8674(21)00363-9
doi: 10.1016/j.cell.2021.03.032
pmc: PMC8491234
mid: NIHMS1708334
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Biomarkers 0
Salicylates 0
tau Proteins 0
Diflunisal 7C546U4DEN
Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) EC 1.2.1.12
p300-CBP Transcription Factors EC 2.3.1.48
p300-CBP-associated factor EC 2.3.1.48
Sirtuin 1 EC 3.5.1.-
salicylsalicylic acid V9MO595C9I

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2715-2732.e23

Subventions

Organisme : NIA NIH HHS
ID : P30 AG013854
Pays : United States
Organisme : NIA NIH HHS
ID : F32 AG043301
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001412
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA217797
Pays : United States
Organisme : RRD VA
ID : IK2 RX002928
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG057862
Pays : United States
Organisme : BLRD VA
ID : I01 BX002439
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG062566
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS098740
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Organisme : NIA NIH HHS
ID : K08 AG065463
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062428
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG066707
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA078586
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests A.A.P. is an inventor on patents related to P7C3. L.G. is a founder of Aeton Therapeutics. No other authors declare competing interests.

Références

Invest Ophthalmol Vis Sci. 2014 Dec 02;55(12):8330-41
pubmed: 25468886
J Biol Chem. 2000 Aug 11;275(32):24977-83
pubmed: 10818091
eNeuro. 2016 Oct 31;3(5):
pubmed: 27822499
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):527-38
pubmed: 16633896
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
J Neurosci. 2007 Aug 29;27(35):9278-93
pubmed: 17728442
Curr Protoc Neurosci. 2010 Jul;Chapter 7:Unit 7.22
pubmed: 20578034
Elife. 2016 May 31;5:
pubmed: 27244239
J Neurol Sci. 2019 Dec 15;407:116495
pubmed: 31655411
Cell Rep. 2014 Sep 25;8(6):1731-1740
pubmed: 25220467
Neurology. 1996 Sep;47(3):711-7
pubmed: 8797469
Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):526-37
pubmed: 11138845
Front Neurosci. 2019 May 01;13:442
pubmed: 31118883
Elife. 2017 Nov 10;6:
pubmed: 29125463
Nat Commun. 2018 Jul 12;9(1):2691
pubmed: 30002366
PLoS One. 2016 Jul 26;11(7):e0159099
pubmed: 27459603
PLoS One. 2017 Jan 9;12(1):e0169650
pubmed: 28068405
Sci Signal. 2018 Mar 20;11(522):
pubmed: 29559585
Clin Chim Acta. 2013 Sep 23;424:216-21
pubmed: 23778024
Acta Neuropathol. 2019 Apr;137(4):585-598
pubmed: 30570675
Cell Rep. 2021 Jan 5;34(1):108588
pubmed: 33406435
J Neurotrauma. 2017 Jan 27;:
pubmed: 27841729
Eur J Cardiothorac Surg. 2015 Sep;48(3):416-20; discussion 420
pubmed: 25559211
Cold Spring Harb Symp Quant Biol. 2018;83:207-217
pubmed: 30787047
Neuron. 2010 Sep 23;67(6):953-66
pubmed: 20869593
Nat Biotechnol. 2009 Jun;27(6):557-9
pubmed: 19483679
Mol Neurodegener. 2017 Aug 15;12(1):59
pubmed: 28810892
Nature. 2006 May 25;441(7092):513-7
pubmed: 16724068
Brain. 2012 Mar;135(Pt 3):807-18
pubmed: 22366796
J Neurosci Methods. 2015 Mar 15;242:82-92
pubmed: 25597910
Cell. 2014 Sep 11;158(6):1324-1334
pubmed: 25215490
Adv Exp Med Biol. 2015;867:125-43
pubmed: 26530364
Hum Mol Genet. 2014 Jan 1;23(1):104-16
pubmed: 23962722
Nat Rev Neurosci. 2010 May;11(5):361-70
pubmed: 20216546
Cell. 2010 Jul 9;142(1):39-51
pubmed: 20603013
Nat Rev Neurol. 2016 Oct;12(10):563-74
pubmed: 27632903
Neurology. 2020 Aug 11;95(6):e623-e636
pubmed: 32641529
Neurology. 2020 Jul 21;95(3):e320-e331
pubmed: 32213642
Antioxid Redox Signal. 2020 Apr 20;32(12):817-833
pubmed: 31657228
J Neurotrauma. 2021 Apr 15;38(8):1086-1106
pubmed: 29020853
Neurotrauma Rep. 2021 Jan 05;2(1):1-13
pubmed: 33748810
Am J Pathol. 1994 Jul;145(1):175-88
pubmed: 7518193
Pain. 2021 Apr 1;162(4):1163-1175
pubmed: 33027220
Nat Commun. 2011;2:252
pubmed: 21427723
Acta Neuropathol Commun. 2018 Jun 29;6(1):52
pubmed: 29958544
Prog Neurobiol. 2011 Dec;95(4):520-34
pubmed: 21524681
J Neurosci. 2009 Oct 21;29(42):13242-54
pubmed: 19846712
J Neurotrauma. 2018 Sep 1;35(17):2104-2116
pubmed: 29648979
Am J Neurodegener Dis. 2012;1(1):99-106
pubmed: 23383382
Acta Neurol Scand. 2017 Jun;135(6):622-627
pubmed: 27439764
Anal Quant Cytol Histol. 2001 Aug;23(4):291-9
pubmed: 11531144
Sci Transl Med. 2019 Sep 4;11(508):
pubmed: 31484787
Cell. 2020 Dec 10;183(6):1699-1713.e13
pubmed: 33188775
Alzheimers Dement. 2012 Jan;8(1):1-13
pubmed: 22265587
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
J Neurol Neurosurg. 2017;4(2):
pubmed: 29276758
Arch Phys Med Rehabil. 2014 May;95(5):986-995.e1
pubmed: 24462839
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27667-27675
pubmed: 33087571
Neurosci Lett. 2013 Sep 27;552:87-91
pubmed: 23933206
EBioMedicine. 2016 Oct;12:118-126
pubmed: 27665050
Nat Cell Biol. 2010 Nov;12(11):1094-100
pubmed: 20972425
Mol Neurodegener. 2016 Jun 29;11(1):47
pubmed: 27356871
ACS Chem Neurosci. 2019 Mar 20;10(3):1595-1602
pubmed: 30421909
Neuron. 2016 Apr 20;90(2):245-60
pubmed: 27041503

Auteurs

Min-Kyoo Shin (MK)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Edwin Vázquez-Rosa (E)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Yeojung Koh (Y)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Matasha Dhar (M)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Kalyani Chaubey (K)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Coral J Cintrón-Pérez (CJ)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Sarah Barker (S)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Emiko Miller (E)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Kathryn Franke (K)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Maria F Noterman (MF)

Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Divya Seth (D)

Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Rachael S Allen (RS)

Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Atlanta, GA, USA; Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, US.

Cara T Motz (CT)

Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Atlanta, GA, USA; Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, US.

Sriganesh Ramachandra Rao (SR)

Departments of Ophthalmology and Biochemistry, and the Neuroscience Graduate Program, SUNY-University at Buffalo, Buffalo, NY, USA; Research Service, VA Western NY Healthcare System, Buffalo, NY, USA.

Lara A Skelton (LA)

Departments of Ophthalmology and Biochemistry, and the Neuroscience Graduate Program, SUNY-University at Buffalo, Buffalo, NY, USA; Research Service, VA Western NY Healthcare System, Buffalo, NY, USA.

Machelle T Pardue (MT)

Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Atlanta, GA, USA; Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, US.

Steven J Fliesler (SJ)

Departments of Ophthalmology and Biochemistry, and the Neuroscience Graduate Program, SUNY-University at Buffalo, Buffalo, NY, USA; Research Service, VA Western NY Healthcare System, Buffalo, NY, USA.

Chao Wang (C)

Gladstone Institute of Neurological Disease, San Francisco, CA, USA.

Tara E Tracy (TE)

The Buck Institute, Novato, CA, USA.

Li Gan (L)

Helen and Robert Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.

Daniel J Liebl (DJ)

The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Jude P J Savarraj (JPJ)

Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Glenda L Torres (GL)

Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Hilda Ahnstedt (H)

Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Louise D McCullough (LD)

Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Ryan S Kitagawa (RS)

Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

H Alex Choi (HA)

Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Pengyue Zhang (P)

Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, USA.

Yuan Hou (Y)

Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Chien-Wei Chiang (CW)

Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, USA.

Lang Li (L)

Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, USA.

Francisco Ortiz (F)

Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, USA.

Jessica A Kilgore (JA)

Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, USA.

Noelle S Williams (NS)

Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, USA.

Victoria C Whitehair (VC)

MetroHealth Rehabilitation Institute, The MetroHealth System, Cleveland, OH; Department of Physical Medicine and Rehabilitation, Case Western Reserve University, School of Medicine, Cleveland, OH USA.

Tamar Gefen (T)

Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Margaret E Flanagan (ME)

Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Pathology, Northwestern University, Chicago, IL, USA.

Jonathan S Stamler (JS)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Mukesh K Jain (MK)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Allison Kraus (A)

Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, USA.

Feixiong Cheng (F)

Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.

James D Reynolds (JD)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Departments of Anesthesiology & Perioperative Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Andrew A Pieper (AA)

Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Weill Cornell Autism Research Program, Weill Cornell Medicine of Cornell University, New York, NY, USA; Department of Neuroscience, Case Western Reserve University, School of Medicine, Cleveland, OH, USA. Electronic address: andrew.pieper@harringtondiscovery.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Métabolisme › Acylation › Acétylation › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Eucaryotes › Animaux › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Anti-inflammatoires non stéroïdiens › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Plaies et blessures › Traumatismes du système nerveux › Traumatismes cranioencéphaliques › Lésions encéphaliques › Lésions traumatiques de l'encéphale › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Hydroxybenzoates › Salicylates › Diflunisal › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxidoreductases acting on aldehyde or oxo group donors › Aldehyde oxidoreductases › Glyceraldehyde 3-phosphate dehydrogenases › Glyceraldehyde 3-phosphate dehydrogenase (phosphorylating) › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Cellules › Neurones › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Neuroprotection › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Hydroxybenzoates › Salicylates › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Sirtuines › Sirtuine-1 › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription CBP-p300 › Reducing acetylated tau is neuroprotective in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › Reducing acetylated tau is neuroprotective in...